CHOP-led Research Study Identifies Key Target in Treatment-Resistant Hemophilia A

Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies, potentially in combination with immune tolerance therapies, to tame the immune response in some patients with severe hemophilia A.

Read more

FDA approvals strengthen Octapharma USA pediatric critical care product portfolio

Octaplas™ and fibryga® receive new product labeling following FDA’s approval of BLA supplements to update therapy research; FDA expands fibryga® indication to include treatment of children under 12 years of age

Read more

Cecelia Calhoun Named Director of the Adolescent-Young Adult Sickle Cell Program at Yale Cancer Center and Smilow Cancer Hospital

Cecelia Calhoun, MD, MSPH, MBA, has been appointed Assistant Professor of Medicine (Hematology) and Assistant Professor of Pediatrics (Hematology/Oncology) at Yale Cancer Center and Smilow Cancer Hospital

Read more

Researchers develop 10-minute COVID-19 diagnostic test that wage workers can afford

Technology based on nanoparticles identifies IgG antibodies and costs only about a fifth of similar devices now on the market. It was developed by scientists at the University of São Paulo and Brazilian startup Biolinker.

Read more

Two Anti-viral Enzymes Transform Pre-Leukemia Stem Cells into Leukemia

Viral infections and space travel similarly trigger inflammation and the enzymes APOBEC3C and ADAR1; UC San Diego researchers are developing ways to inhibit them as a means to potentially lower cancer risk for both astronauts and people on Earth.

Read more

Experience “Innovation Uninterrupted” with Sysmex America at AACC 2020

Sysmex America, Inc., a leading diagnostic solutions company offering hematology, urinalysis, information systems and flow cytometry testing technology for optimal clinical laboratory performance, will be exhibiting virtually at the 72nd AACC Annual Scientific Meeting & Clinical Lab Expo, December 14 – 17.

Read more